Workflow
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
OGNOrganon & (OGN) ZACKS·2025-02-13 16:31

Core Insights - Organon reported 1.59billioninrevenueforQ42024,aslightyear−over−yeardeclineof0.41.59 billion in revenue for Q4 2024, a slight year-over-year decline of 0.4% but a positive surprise of +1.68% over the Zacks Consensus Estimate of 1.57 billion [1] - The earnings per share (EPS) for the quarter was 0.90,whichisanincreasefrom0.90, which is an increase from 0.88 a year ago, and represents a surprise of +4.65% over the consensus estimate of 0.86[1]RevenuePerformancebySegment−RevenuefromEstablishedBrandsintheU.S.forRespiratorywas0.86 [1] Revenue Performance by Segment - Revenue from Established Brands in the U.S. for Respiratory was 13 million, exceeding the estimated 9.49million,markingasignificantyear−over−yearincreaseof+62.59.49 million, marking a significant year-over-year increase of +62.5% [4] - Revenue from Biosimilars in the U.S. for Renflexis was 52 million, below the estimated 57.86million,reflectingayear−over−yeardeclineof−17.557.86 million, reflecting a year-over-year decline of -17.5% [4] - International revenue from Women's Health for NuvaRing was 18 million, surpassing the estimated 16.25million,butshowingayear−over−yeardecreaseof−5.316.25 million, but showing a year-over-year decrease of -5.3% [4] - U.S. revenue from Women's Health for NuvaRing was 6 million, significantly lower than the estimated 8.33million,indicatingayear−over−yeardeclineof−62.58.33 million, indicating a year-over-year decline of -62.5% [4] - Revenue from Women's Health for Nexplanon/Implanon NXT was 258 million, exceeding the estimated 239.15million,withayear−over−yearincreaseof+11.7239.15 million, with a year-over-year increase of +11.7% [4] - Total revenue from Established Brands was 934 million, above the estimated 895.83million,representingayear−over−yearincreaseof+2.1895.83 million, representing a year-over-year increase of +2.1% [4] - Revenue from Women's Health for NuvaRing was 24 million, slightly below the estimated 24.58million,withayear−over−yeardeclineof−31.424.58 million, with a year-over-year decline of -31.4% [4] - Revenue from Women's Health for Ganirelix Acetate Injection was 28 million, exceeding the estimated 26.34million,showingayear−over−yearincreaseof+27.326.34 million, showing a year-over-year increase of +27.3% [4] - Revenue from Biosimilars for Renflexis was 65 million, below the estimated 73.61million,reflectingayear−over−yeardeclineof−15.673.61 million, reflecting a year-over-year decline of -15.6% [4] - Revenue from Biosimilars for Ontruzant was 34 million, slightly below the estimated 35.90million,withayear−over−yeardeclineof−45.235.90 million, with a year-over-year decline of -45.2% [4] - Revenue from Biosimilars for Brenzys was 15 million, significantly lower than the estimated 22.07million,indicatingayear−over−yeardeclineof−46.422.07 million, indicating a year-over-year decline of -46.4% [4] - Revenue from Biosimilars for Aybintio was 6 million, below the estimated $10.13 million, reflecting a year-over-year decline of -33.3% [4] Stock Performance - Over the past month, Organon shares have returned -6.6%, contrasting with the Zacks S&P 500 composite's +3.9% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]